Latest Quarter
2026-04-08
Sunho Biologics Inc (2898.HK)
Revenue
$17.0K
Net Income
-$38.2M
Operating Margin
-243,694.1%
Free Cash Flow
-$158M
Debt / Assets
8.7%
Values are in USD and rounded to the nearest whole number unless noted.
Swipe horizontally to view all columns.
| Income Statement (Quarterly) | 2026-04-08 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 17,000 | 17,000 | 8,500 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 17,000 | 17,000 | 8,500 | 0 |
| Operating Expenses | ||||
| R&D Expenses | 0 | 0 | 0 | 0 |
| SG&A Expenses | 12,678,000 | 12,678,000 | 6,339,000 | 15,006,000 |
| Operating Expenses | 41,445,000 | 41,445,000 | 20,722,500 | 48,415,000 |
| Operating Income | -41,428,000 | -41,428,000 | -20,714,000 | -48,415,000 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Income Before Tax | -38,199,000 | -38,199,000 | -19,099,500 | -43,888,000 |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | -38,199,000 | -38,199,000 | -19,099,500 | -43,888,000 |
| Per Share | ||||
| EPS | -0.26 | -0.26 | -0.13 | -0.28 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Statement (Annual) | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Revenue | 38,000 | 208,000 |
| Cost of Revenue | 0 | 70,000 |
| Gross Profit | 38,000 | 138,000 |
| Operating Expenses | ||
| R&D Expenses | 0 | 0 |
| SG&A Expenses | 30,276,000 | 40,701,000 |
| Operating Expenses | 101,393,000 | 138,000 |
| Operating Income | -101,355,000 | -71,077,000 |
| Interest Expense | 0 | 692,000 |
| Income Before Tax | -79,965,000 | -132,701,000 |
| Income Tax Expense | 0 | 0 |
| Net Income | -79,965,000 | -132,701,000 |
| Per Share | ||
| EPS | -0.62 | -1.43 |
| EPS Diluted | 0.00 | 0.00 |
| Balance Sheet (Quarterly) | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Assets | ||
| Cash and Cash Equivalents | 78,991,000 | 125,074,000 |
| Short Term Investments | 219,468,000 | 84,993,000 |
| Net Receivables | 0 | 0 |
| Inventory | 974,000 | 818,000 |
| Total Current Assets | 492,998,000 | 227,141,000 |
| Property Plant Equipment | 51,804,000 | 50,706,000 |
| Goodwill and Intangibles | 10,000,000 | 10,000,000 |
| Total Assets | 560,735,000 | 290,450,000 |
| Liabilities | ||
| Account Payables | 0 | 0 |
| Short Term Debt | 36,545,000 | 2,178,000 |
| Total Current Liabilities | 44,146,000 | 387,663,000 |
| Long Term Debt | 4,651,000 | 6,896,000 |
| Total Liabilities | 48,797,000 | 394,559,000 |
| Shareholders Equity | ||
| Retained Earnings | -408,081,000 | -328,116,000 |
| Total Shareholders Equity | 511,938,000 | -104,109,000 |
| Balance Sheet (Annual) | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Assets | ||
| Cash and Cash Equivalents | 78,991,000 | 125,074,000 |
| Short Term Investments | 219,468,000 | 84,993,000 |
| Net Receivables | 0 | 0 |
| Inventory | 974,000 | 818,000 |
| Total Current Assets | 492,998,000 | 227,141,000 |
| Property Plant Equipment | 51,804,000 | 50,706,000 |
| Goodwill and Intangibles | 10,000,000 | 10,000,000 |
| Total Assets | 560,735,000 | 290,450,000 |
| Liabilities | ||
| Account Payables | 0 | 0 |
| Short Term Debt | 36,545,000 | 2,178,000 |
| Total Current Liabilities | 44,146,000 | 387,663,000 |
| Long Term Debt | 4,651,000 | 6,896,000 |
| Total Liabilities | 48,797,000 | 394,559,000 |
| Shareholders Equity | ||
| Retained Earnings | -408,081,000 | -328,116,000 |
| Total Shareholders Equity | 511,938,000 | -104,109,000 |
| Cash Flow Statement (Quarterly) | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Operating Activities | ||
| Net Income | -79,965,000 | -132,701,000 |
| Depreciation & Amortization | 9,432,000 | 8,640,000 |
| Stock Based Compensation | 28,348,000 | 30,081,000 |
| Change in Working Capital | -22,044,000 | 6,471,000 |
| Operating Cash Flow | -109,020,000 | -40,653,000 |
| Investing Activities | ||
| Capital Expenditure | -49,260,000 | -1,030,000 |
| Investments | -49,260,000 | -1,030,000 |
| Investing Cash Flow | -345,037,000 | -83,888,000 |
| Financing Activities | ||
| Debt Repayment | 34,300,000 | 0 |
| Common Stock Issued/Repurchased | 419,776,000 | 270,517,000 |
| Dividends Paid | 0 | 0 |
| Financing Cash Flow | 406,530,000 | 255,497,000 |
| Summary | ||
| Free Cash Flow | -158,280,000 | -41,683,000 |
| Net Change in Cash | -46,083,000 | 123,253,000 |
| Cash Flow Statement (Annual) | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Operating Activities | ||
| Net Income | -79,965,000 | -132,701,000 |
| Depreciation & Amortization | 9,432,000 | 8,640,000 |
| Stock Based Compensation | 28,348,000 | 30,081,000 |
| Change in Working Capital | -22,044,000 | 6,471,000 |
| Operating Cash Flow | -109,020,000 | -40,653,000 |
| Investing Activities | ||
| Capital Expenditure | -49,260,000 | -1,030,000 |
| Investments | -49,260,000 | -1,030,000 |
| Investing Cash Flow | -345,037,000 | -83,888,000 |
| Financing Activities | ||
| Debt Repayment | 34,300,000 | 0 |
| Common Stock Issued/Repurchased | 419,776,000 | 270,517,000 |
| Dividends Paid | 0 | 0 |
| Financing Cash Flow | 406,530,000 | 255,497,000 |
| Summary | ||
| Free Cash Flow | -158,280,000 | -41,683,000 |
| Net Change in Cash | -46,083,000 | 123,253,000 |